Tags

Type your tag names separated by a space and hit enter

The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study.
Oral Dis 1997; 3(4):243-6OD

Abstract

OBJECTIVE

The examination of prophylactic efficacy of tretinoin on oral mucositis, post bone marrow transplantation (BMT).

PATIENTS AND METHODS

The study population consisted of 11 patients undergoing BMT. Six tretinoin topically-treated patients (0.25 mg daily of 0.1% tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirements. Concomitant follow-up included conditioning parameters associated with mucositis and engraftment.

RESULTS

The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1.5 vs 3.6; P < 0.02). In the majority of cases the duration of the most severe phase of oral mucositis was shorter in the tretinoin-treated group as compared with the control. Only one patient in the experimental group required morphine analgesics compared with four patients in the control group.

CONCLUSIONS

This preliminary study indicates that the severity of oral mucositis, both objective and subjective, in BMT patients may be reduced by 0.1% topical tretinoin cream, 0.25 mg, administered daily from the beginning of the BMT conditioning regimen until marrow engraftment.

Authors+Show Affiliations

Hospital Oral Medicine Department, Hadassah, Hebrew University, School of Dental Medicine, Jerusalem, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

9643220

Citation

Cohen, G, et al. "The Use of Tretinoin as Oral Mucositis Prophylaxis in Bone Marrow Transplantation Patients: a Preliminary Study." Oral Diseases, vol. 3, no. 4, 1997, pp. 243-6.
Cohen G, Elad S, Or R, et al. The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Dis. 1997;3(4):243-6.
Cohen, G., Elad, S., Or, R., Galili, D., & Garfunkel, A. A. (1997). The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Diseases, 3(4), pp. 243-6.
Cohen G, et al. The Use of Tretinoin as Oral Mucositis Prophylaxis in Bone Marrow Transplantation Patients: a Preliminary Study. Oral Dis. 1997;3(4):243-6. PubMed PMID: 9643220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. AU - Cohen,G, AU - Elad,S, AU - Or,R, AU - Galili,D, AU - Garfunkel,A A, PY - 1998/6/27/pubmed PY - 1998/6/27/medline PY - 1998/6/27/entrez SP - 243 EP - 6 JF - Oral diseases JO - Oral Dis VL - 3 IS - 4 N2 - OBJECTIVE: The examination of prophylactic efficacy of tretinoin on oral mucositis, post bone marrow transplantation (BMT). PATIENTS AND METHODS: The study population consisted of 11 patients undergoing BMT. Six tretinoin topically-treated patients (0.25 mg daily of 0.1% tretinoin cream) were matched with five non-treated control patients comparing mucositis severity, duration and analgetic (morphine) requirements. Concomitant follow-up included conditioning parameters associated with mucositis and engraftment. RESULTS: The mean of oral mucositis peak scores was significantly lower in the tretinoin-treated patients vs the non-treated patients (score 1.5 vs 3.6; P < 0.02). In the majority of cases the duration of the most severe phase of oral mucositis was shorter in the tretinoin-treated group as compared with the control. Only one patient in the experimental group required morphine analgesics compared with four patients in the control group. CONCLUSIONS: This preliminary study indicates that the severity of oral mucositis, both objective and subjective, in BMT patients may be reduced by 0.1% topical tretinoin cream, 0.25 mg, administered daily from the beginning of the BMT conditioning regimen until marrow engraftment. SN - 1354-523X UR - https://www.unboundmedicine.com/medline/citation/9643220/The_use_of_tretinoin_as_oral_mucositis_prophylaxis_in_bone_marrow_transplantation_patients:_a_preliminary_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1354-523X&amp;date=1997&amp;volume=3&amp;issue=4&amp;spage=243 DB - PRIME DP - Unbound Medicine ER -